ULTRAGENYX PHARMACEUTICAL INC. Research and Development in Process
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Research and Development in Process of $75.03 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-17
- ULTRAGENYX PHARMACEUTICAL INC. research and development in process for the quarter ending 2022-12-31 was -$201.00K.
- ULTRAGENYX PHARMACEUTICAL INC. research and development in process for the quarter ending 2021-12-31 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. research and development in process for fiscal 2022 was $75.03M.
- ULTRAGENYX PHARMACEUTICAL INC. research and development in process for fiscal 2021 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. research and development in process for fiscal 2020 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|
| 2022-12-31 | -$201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $75.03M 10-K · filed 2023-02-17 | |
| 2022-09-30 | $75.23M 10-Q · filed 2022-11-03 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $0.00 10-K · filed 2023-02-17 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |